Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ —  Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS ® (carfilzomib) in combination with

Original Source